Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2475-2484

  Toyonaga, Jiro ^a   Tsuruya, Kazuhiko ^a   Ikeda, Hirofumi ^a   Noguchi, Hideko ^a   Yotsueda, Hideki ^a   Fujisaki, Kiichiro ^a   Hirakawa, Makoto ^a   Taniguchi, Masatomo ^a   Masutani, Kohsuke ^a   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

aldosterone; diabetic nephropathy; mineralocorticoid receptor; NADPH oxidase; podocyte; reactive oxygen species

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALDOSTERONE; CASPASE 3; DESMIN; GLUCOSE; MINERALOCORTICOID RECEPTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SPIRONOLACTONE; STREPTOZOCIN; SYNAPTOPODIN; WT1 PROTEIN;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; GLOMERULUS; HYPERGLYCEMIA; HYPOALDOSTERONISM; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MALE; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; STREPTOZOCIN DIABETES; UPREGULATION;

ALDOSTERONE ANTAGONISTS; ANIMALS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; HYPERGLYCEMIA; MALE; NADPH OXIDASE; OXIDATIVE STRESS; PODOCYTES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPIRONOLACTONE;

EID: 79961096910     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq750     Document Type: Article

References (57)

1. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-2320 (Pubitemid 38670018)
2. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002;13:3005-3015 (Pubitemid 35386921)
3. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006;69:2131-2147 (Pubitemid 43882099)
4. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001;108:1583-1587 (Pubitemid 33144868)
5. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002;61:1475-1485 (Pubitemid 34304509)
6. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts longterm urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999;42:1341-1344 (Pubitemid 29500971)
7. White KE, Bilous RW, Marshall SM et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002;51:3083-3089
8. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005;18:44-49 (Pubitemid 40187348)
9. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006;70:2116-2123 (Pubitemid 44871374)
10. Shibata S, Nagase M, Yoshida S et al. Podocyte as the target for aldosterone roles of oxidative stress and Sgk1. Hypertension 2007;49:355-364 (Pubitemid 46143013)
11. Ikeda H, Tsuruya K, Toyonaga J et al. Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int 2009;75:147-155
12. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000;36:449-467
13. Fujisawa G, Okada K, Muto S et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004;66:1493-1502 (Pubitemid 39298382)
14. Miric G, Dallemagne C, Endre Z et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001;133:687-694 (Pubitemid 32642874)
15. Yuan J, Jia R, Bao Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 2007;8:118-126 (Pubitemid 350148448)
16. Guo C, Martinez-Vasquez D, Mendez GP et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006;147:5363-5373 (Pubitemid 44790591)
17. Han KH, Kang YS, Han SY et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006;70:111-120 (Pubitemid 44000127)
18. Han SY, Kim CH, Kim HS et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006;17:1362-1372
19. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005;68:2829-2836 (Pubitemid 43251030)
20. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70:536-542 (Pubitemid 44141580)
21. Susztak K, Raff AC, Schiffer M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;55:225-233 (Pubitemid 43343319)
22. Tsuruya K, Ninomiya T, Tokumoto M et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003;63:72-82 (Pubitemid 35463908)
23. Ohtsubo T, Ohya Y, Nakamura Y et al. Accumulation of 8-oxodeoxyguanosine in cardiovascular tissues with the development of hypertension. DNA Repair 2007;6:760-769 (Pubitemid 46670090)
24. Gross ML, Adamczak M, Rabe T et al. Beneficial effects of estrogens on indices of renal damage in uninephrectomized SHRsp rats. J Am Soc Nephrol 2004;15:348-358 (Pubitemid 38140775)
25. Wang L, Fields TA, Pazmino K et al. Activation of Gaq-coupled signaling pathways in glomerular podocytes promotes renal injury. J Am Soc Nephrol 2005;16:3611-3622 (Pubitemid 46211282)
26. Hirakawa M, Tsuruya K, Yotsueda H et al. Expression of synaptopodin and GLEPP1 as markers of steroid responsiveness in primary focal segmental glomerulosclerosis. Life Sci 2006;79:757-763 (Pubitemid 43975128)
27. Mundel P, Reiser J, Zúñiga Mejía Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997;236:248-258 (Pubitemid 27452369)
28. Tsuruya K, Tokumoto M, Ninomiya T et al. Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol 2003;285:F208-F218 (Pubitemid 36871193)
29. Miyata K, Rahman M, Shokoji T et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005;16:2906-2912 (Pubitemid 44743488)
30. Kitada M, Koya D, Sugimoto T et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003;52:2603-2614 (Pubitemid 37210551)
31. Steffes MW, Schmidt D, McCrery R et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001;59:2104-2113 (Pubitemid 32467602)
32. Menini S, Iacobini C, Oddi G et al. Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia 2007;50:2591-2599 (Pubitemid 350060642)
33. Greiber S, Müller B, Daemisch P et al. Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophagecolony- stimulating factor. J Am Soc Nephrol 2002;13:86-95 (Pubitemid 34042015)
34. Binder CJ, Weiher H, Exner M et al. Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol 1999;154:1067-1075 (Pubitemid 29169741)
35. Marshall CB, Pippin JW, Krofft RD et al. Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006;70:1962-1973 (Pubitemid 44863385)
36. Hinokio Y, Suzuki S, Hirai M et al. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia 1999;42:995-998 (Pubitemid 29369608)
37. Ha H, Kim C, Son Y et al. DNA damage in the kidneys of diabetic rats exhibiting microalbuminuria. Free Radic Biol Med 1994;16:271-274 (Pubitemid 24117509)
38. Sano T, Umeda F, Hashimoto T et al. Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia 1998;41:1355-1360 (Pubitemid 28488764)
39. Kakimoto M, Inoguchi T, Sonta T et al. Accumulation of 8-hydroxy-2'-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes 2002;51:1588-1595 (Pubitemid 34826629)
40. De Petris L, Hruska KA, Chiechio S et al. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 2007;22:3442-3450 (Pubitemid 350212514)
41. Schambelan M, Stockigt JR, Biglieri EG. Isolated hypoaldosteronism in adults. A renin-deficiency syndrome. N Engl J Med 1972;287:573-578
42. Tuck ML, Sambhi MP, Levin L. Hyporeninemic hypoaldosteronism in diabetes mellitus. Studies of the autonomic nervous system's control of renin release. Diabetes 1979;28:237-241 (Pubitemid 9162304)
43. Liu YJ, Nakagawa Y, Toya K et al. Effects of spironolactone on systolic blood pressure in experimental diabetic rats. Kidney Int 2000;57:2064-2071 (Pubitemid 30252298)
44. Náray-Fejes-Tóth A, Canessa C, Cleaveland ES et al. Sgk is an aldosterone-induced kinase in the renal collecting duct. Effects on epithelial Na+ channels. J Biol Chem 1999;274:16973-16978
45. Vallon V, Lang F. New insights into the role of serum-and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure. Curr Opin Nephrol Hypertens 2005;14:59-66 (Pubitemid 40110701)
46. Chen SY, Bhargava A, Mastroberardino L et al. Epithelial sodium channel regulated by aldosterone-induced protein Sgk. Proc Natl Acad Sci USA 1999;96:2514-2519 (Pubitemid 29117947)
47. Quinkler M, Zehnder D, Eardley KS et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005;112:1435-1443 (Pubitemid 41291769)
48. Kumar JM, Brooks DP, Olson BA et al. Sgk, a putative serine/threonine kinase, is differentially expressed in the kidney of diabetic mice and humans. J Am Soc Nephrol 1999;10:2488-2494
49. Hills CE, Bland R, Bennett J et al. High glucose up-regulates ENaC and SGK1 expression in HCD-cells. Cell Physiol Biochem 2006;18:337-346 (Pubitemid 44948044)
50. Saad S, Stevens VA, Wassef L et al. High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney Int 2005;68:985-997 (Pubitemid 43246415)
51. Etoh T, Inoguchi T, Kakimoto M et al. Increased expression of NAD (P) H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 2003;46:1428-1437 (Pubitemid 37297214)
52. Eid AA, Gorin Y, Fagg BM et al. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 2009;58:1201-1211
53. Taira M, Toba H, Murakami M et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol 2008;589:264-271
54. Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005;46:584-590 (Pubitemid 41379384)
55. Lee SH, Yoo TH, Nam BY et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009;297:F1381-F1390
56. Shibata S, Nagase M, Yoshida S et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008;14:1370-1376
57. Tsubouchi H, Inoguchi T, Sonta T et al. Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 2005;39:444-452 (Pubitemid 41021643)